Tromsø, Norway, 04 February 2019 - Biotec Pharmacon (OSE: Biotec) announces
today that its subsidiary Biotec BetaGlucans has been awarded up to NOK 8
million in a grant by the Research Council of Norway for a project titled
"Bioactive wound healing dressing with beta-glucan for treatment of hard-to-heal
wounds". The project is to be supported over 4 years.
The grant has been awarded from the User-driven Research-based Innovation
Programme (BIA), and the focus of the project will be to develop first of its
kind bioactive gel-forming fibre dressings. These dressings will contain soluble
beta-glucan (SBG®) for the treatment of hard-to-heal wounds by re-activating the
healing process.
The project aims to develop new and cost-effective wound healing devices for the
treatment of large hard-to-heal wounds, exuding wounds (burns and ulcers), donor
-site wounds, and wounds on mucosal surfaces.
Established in 2006, the BIA programme is one of the largest programmes at the
Research Council and is a key partner for Norwegian trade and industry. This
broad-based programme supports high-quality R&D projects with good business and
socio-economic potential.
The award is subject to successful contract negotiations between the parties.
Christian Jørgensen, CEO, said:
"We are pleased to have been awarded this grant, which serves as a great
testament to the hard work being done at Biotec BetaGlucans. It will help us
develop a broader set of treatments for the many people suffering from different
types of hard-to-heal wounds."
-ENDS-
For more information, please contact:
Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Email: ir@biotec.no
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Deborah Biotecpharmacon@instinctif.com
Bell
About Biotec Pharmacon ASA
Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.
The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsoe to offer niche and high tech products in
several biotech segments.
ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.
Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.
Biotec Pharmacon's unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.
For more information, please visit the website: www.biotec.no.
About Biotec BetaGlucans
BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan
(BG) products derived from the cell wall of the Saccharomyces cerevisiae.
The active pharmaceutical ingredients display immunomodulatory properties
addressing high unmet healthcare needs, such as chronic wound healing or cancer.
Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the
wound healing product (Woulgan®) and is also being tested in a R&D programme as
an adjuvant for immunotherapeutic cancer treatments.
For more information, please visit: https://biotec.no/about-us/biotec
-betaglucans/.